Plato Investment Management Ltd Acquires New Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Plato Investment Management Ltd acquired a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,895 shares of the specialty pharmaceutical company’s stock, valued at approximately $228,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of JAZZ. Allspring Global Investments Holdings LLC grew its position in shares of Jazz Pharmaceuticals by 0.6% in the first quarter. Allspring Global Investments Holdings LLC now owns 16,082 shares of the specialty pharmaceutical company’s stock valued at $1,937,000 after purchasing an additional 99 shares during the last quarter. Waterfront Wealth Inc. increased its stake in shares of Jazz Pharmaceuticals by 1.2% in the fourth quarter. Waterfront Wealth Inc. now owns 8,633 shares of the specialty pharmaceutical company’s stock valued at $1,062,000 after buying an additional 103 shares during the period. ProShare Advisors LLC raised its holdings in Jazz Pharmaceuticals by 1.4% during the 1st quarter. ProShare Advisors LLC now owns 7,439 shares of the specialty pharmaceutical company’s stock worth $896,000 after purchasing an additional 105 shares during the last quarter. Prime Capital Investment Advisors LLC lifted its holdings in Jazz Pharmaceuticals by 4.3% in the fourth quarter. Prime Capital Investment Advisors LLC now owns 2,646 shares of the specialty pharmaceutical company’s stock valued at $325,000 after buying an additional 108 shares during the period. Finally, Ontario Teachers Pension Plan Board boosted its position in shares of Jazz Pharmaceuticals by 0.4% during the 4th quarter. Ontario Teachers Pension Plan Board now owns 29,749 shares of the specialty pharmaceutical company’s stock valued at $3,659,000 after purchasing an additional 108 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $109.65, for a total value of $548,250.00. Following the completion of the transaction, the executive vice president now owns 36,629 shares of the company’s stock, valued at approximately $4,016,369.85. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 4.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Robert W. Baird cut their target price on Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a research note on Thursday. Needham & Company LLC lowered their target price on shares of Jazz Pharmaceuticals from $208.00 to $205.00 and set a “buy” rating on the stock in a report on Thursday. Royal Bank of Canada decreased their target price on shares of Jazz Pharmaceuticals from $175.00 to $174.00 and set an “outperform” rating on the stock in a report on Thursday. Barclays dropped their price target on Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Friday, May 3rd. Finally, Morgan Stanley lowered their price target on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating on the stock in a research report on Friday, July 12th. Four research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $175.20.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ traded up $4.13 during trading hours on Thursday, hitting $114.38. The company had a trading volume of 2,239,512 shares, compared to its average volume of 686,145. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $146.70. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 1.38. The firm has a market cap of $7.21 billion, a P/E ratio of 23.58, a price-to-earnings-growth ratio of 1.73 and a beta of 0.58. The business has a fifty day simple moving average of $107.47 and a 200-day simple moving average of $114.15.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 EPS for the quarter, missing the consensus estimate of $3.53 by ($1.55). The business had revenue of $901.98 million during the quarter, compared to the consensus estimate of $938.99 million. Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. Equities analysts predict that Jazz Pharmaceuticals plc will post 15.31 EPS for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.